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Objectives: There is a lack of understanding of health related quality of life (HRQoL) in chronic liver disease (CLD).
With the rising prevalence of alcohol and obesity driven CLD, and the increasing ability to screen for fibrosis, it is
important to understand the impact of the diagnostic process for patients.
Study design: Prospective cohort study.
Methods: A cohort study conducted utilising the Nottingham Adult Liver Disease Stratification Pathway, UK. All
patients referred as high risk for CLD (due to metabolic, alcohol or abnormal liver enzymes) completed the EQ-5D
before diagnosis and at three and 12 months after. HRQoL was investigated by domain, CLD severity (transient
elastography) and temporally.
Results: 493 patients participated with 300 (60.9%) completing at least one follow-up HRQoL assessment.
Pre-diagnosis the median (IQR) utility index was 0.75 (0.61–0.85) and visual analogue scale was 75/100 (60–90).
The median utility index was significantly lower amongst those with advanced liver disease compared to those
without at all time points (baseline 0.68 vs 0.77, three-months 0.65 vs 0.79, 12-months 0.69 vs 0.84, all p < 0.05).
The majority of decrements in HRQoL score were in the pain domain.
Conclusions: There was no reduction, over three or 12 months, in HRQoL identified amongst high-risk individuals
progressing through the diagnostic pathway. Overall the HRQoL of participants at high risk for the development
of significant CLD was lower than the UK and regional (East Midlands) norms. Furthermore, we found reduced
HRQoL in those going on to receive a diagnosis of advanced liver disease compared to those without.1. Introduction
Chronic liver disease (CLD) is increasing in prevalence worldwide,
estimated to affect over one billion people globally and is associated with
over one million deaths and 40 million disability adjusted life years lost
per year [1]. The increasing prevalence in the western world is largely
being driven by the rise in metabolic syndrome related non-alcoholic
fatty liver disease (NAFLD) and alcohol related liver disease (ARLD) [2,
3]. Given the rising prevalence of liver disease, knowledge of the
resulting impact on health related quality of life (HRQoL) is essential to
support health service planning.
There is a paucity of information on HRQoL in CLD beyond the
experience of hepatitis C virus [4,5]. CLD is thought to be a largely
asymptomatic disease until the later stages when symptoms ofy and Public Health, University o
c.uk, joanne.morling@nottingham
vier Ltd on behalf of The Royal Sdecompensation (ascites, encephalopathy, variceal bleeding) dominate.
As a result, whilst it could be hypothesised that early CLD would have
limited impact on HRQoL compared to later more significant disease, this
is as yet unknown. Furthermore, the impact of receiving a diagnosis,
when otherwise well (which is akin to screening programmes), is also
unknown.
This study utilises The Nottingham Adult Liver Disease Stratification
Pathway, a community-based healthcare pathway in Nottingham, UK
[6], which aims to support the diagnosis of early and later stage CLD in
individuals deemed to be at high risk within general practice. We aimed
to determine the impact of a diagnosis of CLD on HRQoL in the short
(three month) and medium (12 month) term in individuals at high risk of
CLD in the community and how this differed by diagnosed liver disease
severity.f Nottingham, City Hospital Campus, Clinical Sciences Building, Hucknall Road,
.ac.uk (J.R. Morling).
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2.1. Setting
The Nottingham Adult Liver Disease Stratification Pathway (‘the
Nottingham Liver Pathway’) was commissioned by the Greater Not-
tingham Clinical Commissioning Groups in late 2016. This region is
suburban including approximately 106 GP practices and a population of
approximately 700,000.
The pathway allows primary care professionals to refer any patient
meeting criteria for being at high risk of CLD for transient elastography to
assess liver health. Any patient meeting the pathway criteria (see “Par-
ticipants” below) can be opportunistically referred for liver fibrosis
assessment at the local hospital. On attendance patients undergo tran-
sient elastography, are provided with brief lifestyle advice and are
informed of their scan result. Results are also returned by letter to the
patients GP. Advice provided to the GP varies by risk stratification: no
significant liver disease – repeat transient elastography in five years,
significant liver disease – consider secondary care referral or repeat
transient elastography in three years, advanced liver disease –refer to
secondary care hepatology.
All patients attending this pathway during the period between August
2016 and July 2017 were offered the opportunity to be included in the
study. They were re-contacted by telephone at three and 12 months post
assessment for follow-up data collection. Time points were selected to
capture any initial impact of the diagnosis (three months) and any
persistence of impact (12 months).
The at-risk and assessed populations are described in detail in prior
publications. In brief, from detailed piloting we determined that
approximately 10% of the adult population in the area had a GP record of
either type 2 diabetes or alcohol excess and that when offered the referral
opportunity approximately 50% agreed [6,7].
2.2. Participants
Inclusion criteria were: adult (aged 18þyears), meeting high-risk of
liver disease criteria in the Nottingham liver pathway, attending for
transient elastography. The high-risk criteria for referral were: harmful
alcohol consumption, defined as men who drink over 50 units and
women who drink over 35 units of alcohol per week; type 2 diabetes or
metabolic syndrome, defined as ‘a GP diagnosis’; incidental fatty liver on
ultrasound; or asymptomatic abnormal liver enzymes without other
cause and defined as AST/ALT >0.8. Patients with type 2 diabetes,
metabolic syndrome or incidental fatty liver additionally required a fatty
liver index (FLI) > 60.
2.3. Data collection
2.3.1. HRQoL
The primary outcome was change in HRQoL, between pre-diagnosis
and three months and between pre-diagnosis and 12 months. Immedi-
ately prior to undergoing transient elastography all patients agreeing to
participate completed the generic preference based quality of life scale
EQ-5D-5L [8] whilst they were unaware of their liver disease status.
Paper questionnaires were completed by individuals at the clinic prior to
receiving their scan with the support of trained research nurses where
necessary. They were then contacted by telephone at approximately
three and 12 months post liver assessment for follow-up EQ-5D-5L
assessment. Three trained researchers collected the follow-up data blind
to all the prior results of the participants including EQ-5D, liver disease
status and referral reason.
The EQ-5D comprises two components: the descriptive system and
the visual analogue scale (VAS). The descriptive system considers five
dimensions: mobility, self-care, usual activities, pain/discomfort and
anxiety/depression. Each of these dimensions can be scored by the pa-
tient using five levels of severity: no problems, slight problems, moderate2problems, severe problems and extreme problems. The five domains and
five levels can be used to describe 3125 individual health states [9]. The
EQ VAS records the patient’s self-rated health on a vertical scale from 0 to
100. A score of 100 means ‘the best health you can imagine’ and 0 ‘the
worst health you can imagine’.
HRQoL utility weights were calculated using the validated EQ-5D-5L
cross-walk algorithm [10] to provide a score on a 0.594 to 1 scale with
negative scores indicating states worse than death and 1 being the best
possible health imaginable.
2.3.2. Transient elastography
Following pre-diagnosis EQ-5D questionnaire completion partici-
pants underwent transient elastography. Transient elastography using
Fibroscan was undertaken in-line with standard protocols (4-h fast) using
either the M or XL probe as appropriate and described in detail elsewhere
[7]. Transient elastography has been well validated for the diagnosis of
significant liver fibrosis (Metavir F2þ) with area under the receiver
operating curve of >0.9 [11]. Consequently, transient elastography re-
sults were used to categorise liver fibrosis severity into: no significant
liver disease (<8 kPa), significant liver disease (8–14.9 kPa), advanced
liver disease (15 kPa).
2.4. Analysis
Baseline characteristics were compared for those with and without
advanced liver disease by: age, sex, referral reason, pre-diagnosis utility
index and pre-diagnosis VAS using t-test, Mann-Whitney U test or Chi Sq
test as appropriate.
Mean (sd) and median (range) values for the utility index were
calculated by sex, age, referral reason and liver fibrosis category at pre-
diagnosis, three months post diagnosis and 12 months post diagnosis.
Change in HRQoL score was calculated (score at timeA – score at
timeB) for the periods pre-diagnosis to three months and pre-diagnosis to
12 months for participants with paired data available and analysed using
the Wilcoxon signed rank test.
A sensitivity analysis was undertaken limited to only those patients
with data available at all three time points.
2.5. Ethical approval
Ethical approval for the study was given by NHS East Midlands -
Leicester Central Research Ethics Committee (ref.13/EM/0123) and the
study is registered with clinicaltrials.gov (ID NCT02037867).
All potential participants received an in information letter about the
study at the time of invite to the transient elastography clinic and then
had the opportunity to discuss the project with a trained research nurse
prior to completing written informed consent.
3. Results
3.1. Participant characteristics
During the study period 1169 patients were referred to the pathway
with 844 (72.2%) attending. Of these, 520 (61.6%%) agreed to partici-
pate. Twenty-seven patients were unable to complete both the EQ-5D and
transient elastography at the liver assessment, producing a study cohort
of N ¼ 493 (94.8%). Of these n ¼ 300 (60.9%) participants completed at
least one follow-up EQ-5D survey and n ¼ 148 (49.3%) completed all
three (Fig. 1). Those participating in the research were slightly younger
but otherwise similar to those who declined to take part (Table 1).
The mean age of study participants was 55.7 years, with 48.4% male.
Those participating in follow-up were more likely to be female (54.0% vs
47.9%) and older (mean 57.3 vs 53.1 years) (Table 1).
Fig. 1. Participant flow chart.
Table 1
Patient characteristics.
Study cohort
(pre-diagnosis)
N ¼ 493
Non consenting/
missing data
cohort
N ¼ 351
Included vs
no included
Without any
follow-up n ¼
193
With any follow-
up n ¼ 300
With 3 month
EQ5D follow-up
N ¼ 218
With 12 month
EQ5D follow-up
N ¼ 238
With vs
without
follow-up
Age, years 55.7 (13.3) 57.9 (13.9) p ¼ 0.014 53.1 (13.7) 57.3 (13.2) 57.1 (19.6) 57.6 (13.4) p ¼ 0.001
Male 48.4% (237) 45.3% (159) p ¼ 0.408 52.1 (100) 46.0% (137) 42.6% (89) 47.9% (113) p ¼ 0.219
Referral reason:
Alcohol excess
NALFD
NAFLD& alcohol
excess
Abnormal liver
enzymes
19.7% (95)
38.2% (184)
2.9% (14)
39.2% (189)
21.1% (74)
38.4% (135)
4.4% (15)
36.2% (127)
p ¼ 0.579 19.3% (37)
38.0% (73)
4.2% (8)
38.5% (74)
20.0% (58)
38.3% (111)
2.1% (6)
39.7% (115)
20.2% (41)
37.9% (77)
2.0% (4)
39.9% (81)
20.8% (48)
35.9% (82)
2.2% (5)
4.1% (95)
p ¼ 0.611
Transient
elastography,
kPa
5.7 (4.4–7.7) 5.7 [4.4–7.8] p ¼ 0.755 5.5 (4.3–7.7) 5.9 (4.4–7.9) 6.0 (4.7–7.8) 5.7 (4.4–8.2) p ¼ 0.267
EQ-5D index (pre-
diagnosis)
0.75
(0.61–0.85)
– – 0.77 (0.63–0.88) 0.74
(0.57–0.84)
0.74 (0.56–0.84) 0.75 (0.61–0.84) p ¼ 0.306
VAS (pre-
diagnosis)
75 (60–90) – – 75 (53–90) 80 (60–90) 80 (60–90) 80 (60–90) p ¼ 0.261
Values are mean(sd), median(IQR) or %(n); kPa kilopascals; NAFLD non-alcohol fatty liver disease; VAS visual analogue scale.
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3.2.1. Utility index
Pre-diagnosis the median (IQR) utility index was 0.75 (0.61–0.85)
and VAS was 75/100 (60–90). Males had significantly higher HRQoL
than females (median index 0.77 vs 0.74, p ¼ 0.032). There was no
significant difference in pre-diagnosis utility index by age or referral3reason (Table 2).
Those participants with definite fibrosis had significantly lower utility
index than those without (0.68 vs 0.77, p ¼ 0.001).
3.2.2. Domains
Full domain data is detailed in Table 2.
Amongst all participants, by domain, self-care showed the highest
Table 2
Pre-diagnosis health related quality of life.
% (n) no problems Median utility index VAS
Mobility Pain Anxiety ADLs Selfcare
All 55.2 (272) 30.6 (151) 46.2 (228) 56.8 (280) 81.1 (400) 0.75 75
Sex
Male 58.6 (139) 35.4 (84) 53.2 (126) 57.8 (137) 81.0 (192) 0.77 80
Female 51.4 (130) 25.7 (65) 40.3 (102) 55.3 (140) 81.0 (205) 0.74 70
Age
<40years 67.0 (39) 37.9 (22) 37.9 (22) 69.0 (40) 91.4 (53) 0.77 75
40-49 years 58.1 (54) 39.8 (37) 43.0 (40) 52.7 (49) 79.6 (74) 0.77 70
50-59years 56.9 (82) 33.3 (48) 35.4 (51) 52.8 (76) 78.5 (113) 0.74 75
60-69years 49.6 (65) 22.1 (29) 56.5 (74) 55.7 (73) 78.4 (104) 0.74 80
70 þ years 35.6 (21) 22.0 (13) 61.0 (36) 61.0 (36) 81.4 (48) 0.77 80
Referral reason
Alcohol excess 53.7 (51) 30.5 (29) 32.6 (31) 45.3 (43) 81.1 (77) 0.74 75
NALFD 51.9 (96) 29.9 (55) 47.6 (89) 54.5 (101) 78.6 (145) 0.74 75
Abnormal liver enzymes 58.4 (110) 31.1 (59) 52.1 (98) 63.7 (120) 83.7 (158) 0.77 80
Fibrosis category
No significant liver disease 60.1% (227) 31.7% (120) 48.4% (183) 61.1% (231) 83.1% (314) 0.77 80
Significant liver disease 42.9% (39) 28.6% (26) 35.2% (18) 46.2% (42) 75.8% (69) 0.69 75
Advanced liver disease 25.0% (6) 20.8% (5) 54.2% (13) 29.2% (7) 70.8% (17) 0.68 70
ADLs activities of daily living; NAFLD non-alcohol fatty liver disease; VAS visual analogue scale.
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(56.8%), mobility (55.2%), anxiety and depression (46.2%), and with
most difficulties reported for pain (30.6% no problems).
Females were more likely to report deficits in all domains than males,
with the biggest differences in anxiety (12.9% difference). As age
increased, so did the proportion of participants reporting problems with
pain (<40years 62.1% vs  70years 78.0% with problems) and mobility
(<40years 33.0% vs  70years 54.4% with problems). Conversely, the
proportion of participants reporting problems with anxiety fell as age
increased (<40years 62.1% vs  70years 39.0% with problems). Daily
activities and self-care remained static with age.
Referral reason was not associated with domain deficits with the
exception of anxiety and daily activities. Those with alcohol excess had
more problems than those with NAFLD, who in turn were higher than
those with abnormal liver enzymes for both anxiety and daily activities
(67.4, 52.4, 47.9%with anxiety problems and 54.7, 45.5 and 36.6% with
daily activity problems respectively).
Pre-diagnosis, as liver disease severity increased so did the proportion
of patients reporting problems with mobility, pain, daily activities and
self-care. The largest deficits were in mobility (35.1% difference) and
daily activities (31.9% difference).Table 3
EQ-5D score over time.
Median utility index
Pre-diagnosis n ¼ 300 3 months n ¼ 218 12 month
All 0.75 0.77 0.81
Sex
Male 0.77 0.84 0.85
Female 0.74 0.74 0.77
Age
<40years 0.77 0.88 0.88
40-49 years 0.77 0.66 0.82
50-59years 0.74 0.77 0.80
60-69years 0.74 0.77 0.75
70 þ years 0.77 0.79 0.86
Referral reason
Alcohol excess 0.74 0.79 0.77
NALFD 0.74 0.77 0.77
Abnormal liver enzymes 0.77 0.77 0.85
Fibrosis category
No significant liver disease 0.77 0.79 0.84
Significant liver disease 0.69 0.70 0.80
Advanced liver disease 0.68 0.65 0.69
NAFLD non-alcohol fatty liver disease; VAS visual analogue scale.
43.3. Post-diagnosis
3.3.1. Utility index
Overall, the median utility index increased over time, from 0.75 to
0.81. This pattern was consistent across age, sex and referral reason
(Table 3).
At both follow-up time points the median utility score for those with
significant liver disease was lower than for those without (three months
0.68 vs 0.77, p ¼ 0.029, 12 months 0.69 vs 0.84, p ¼ 0.331).
In the initial three months post-diagnosis there were no statistically
significant changes in median index utility in any of the liver disease
severity categories (Table 4). Over the longer post-diagnosis period to 12
months those with no significant liver disease or significant liver disease
demonstrated a measurable increase in HRQoL (mean utility index
change þ0.06, p < 0.001 and þ 0.08, p ¼ 0.006 respectively). In the
advanced liver disease group the HRQoL remained static (mean utility
index change 0.01, p ¼ 0.965) (Table 4 and Fig. 2).
3.3.2. Domains
Over time there were no changes in the domain patterns across age,
sex and referral reason (Appendix A).Median VAS
s n ¼ 238 Pre-diagnosis n ¼ 300 3 months n ¼ 218 12 months n ¼ 238
75 75 80
80 80 80
70 75 80
75 80 80
70 68 75
75 80 80
80 75 80
80 80 80
75 80 80
75 75 75
80 75 80
80 80 80
75 70 80
70 66 75
Table 4
Mean change in EQ-5D score following diagnosis by disease severity.
Pre-diagnosis to 3
months
Pre-diagnosis to 12
months
All n ¼
218
þ0.01
(0.21)
p ¼
0.223
n ¼
238
þ0.06
(0.20)
p <
0.001
No significant
liver disease
n ¼
163
þ0.01
(0.21)
p ¼
0.291
n ¼
174
þ0.06
(0.20)
p <
0.001
Significant liver
disease
n ¼
42
þ0.03
(0.19)
p ¼
0.285
n ¼
51
þ0.08
(0.21)
p ¼
0.006
Advanced liver
disease
n ¼
13
0.05
(0.20)
p ¼
0.661
n ¼
13
0.01
(0.22)
p ¼
0.965
Values are mean (sd).
Fig. 2. EQ-5D index over time by fibrosis category.
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severities are shown in Fig. 3 (and Appendix A). There was little change
in proportions reporting problems with self-care over time for all liver
disease severity categories. For mobility, pain and daily activities all
three liver disease severity categories saw an increase in proportions
reporting no problems over time, however there was an increase in the
difference between no significant liver disease and advanced liver disease
for mobility and daily activities (35.1–40.5% and 10.9–27.5% difference
respectively). Anxiety was the only domain showing the converse; as
liver disease becomes severe the proportion reporting anxiety problems
falls. Additionally, the proportion of patients reporting anxiety problems
falls over time.3.4. Sensitivity analysis
In sensitivity analysis, restricted to only those participants with
measures at all three time points, the results remained similar (Appendix
B).
4. Discussion
We have identified no reduction in participants HRQoL experiencing
our novel diagnostic pathway for CLD. We did however find that those
participants diagnosed with either no significant liver disease or signif-
icant liver disease had improved HRQoL by 12 months post the diag-
nostic process.
It is unclear why patients HRQoL improved over time. It is possible
that the anxiety of the liver assessment caused an artificial lowering of
the baseline measures. Alternatively, it is probable that following the
assessment that a definitive diagnosis had been made (absence or pres-
ence of liver disease) provided a degree of relief and increase in HRQoL.
A final consideration is regression to the mean [12].
It has been raised as a concern that putting asymptomatic patients
through a diagnostic pathway for a condition with no direct intervention
available could cause more harm than good. In other disease areas a
diagnosis can lead to symptom relief and treatment resulting in an in-
crease in HRQoL [13], but this is not the scenario in chronic liver disease.
For those with significant fibrosis there is the potential for hepatocellular
carcinoma and variceal screening, but for other participants the focus is
on lifestyle change. We found no evidence of any decrement in HRQoL,
with index scores showing no significant difference at each time point. As
one might expect, HRQoL had marginally declined in the group diag-
nosed with advanced liver disease post-diagnosis, however it had
returned to pre-diagnosis levels by 12 months. No reduction was seen in
the no or possible fibrosis groups. It is notable that at three months all
liver disease severity groups had an increase in “no problems” responses
for anxiety and depression, supporting the idea that the pathway is not
causing any detriment to well-being. This is akin to other ‘screening’ type
studies which have similarly found no detriment to HRQoL during the
process – for example in PSA screening for prostate cancer [14] and type
2 diabetes [15]. Furthermore, studies in diabetes show that those with
screen diagnosed disease (as opposed to routine symptomatic diagnosis)5had a better quality of life [16].
Additionally, we have demonstrated that HRQoL is lower in people at
high risk of chronic liver disease compared to the UK and regional (East
Midlands) norms (0.75 vs 0.80 and 0.85 respectively for ages
55–64years) [17]. Following investigation and diagnosis, patients with
advanced liver disease have an even lower HRQoL than those without
significant liver disease. Post-diagnosis those with advanced liver disease
maintain their HRQoL whereas those with less severe or no liver disease
improve. Overall there was no detriment in HRQoL identified amongst
high-risk individuals progressing through the diagnostic pathway.
Similar to other general population studies we found that females had
lower HRQoL than males and that HRQoL decreased with age. Interest-
ingly, the deficit in our high risk of CLD population compared to the
general population was particularly notable amongst younger patients
where the difference was as much as 0.16 (age<49 years), with the older
age group demonstrating similar deficits [17].
The major deficits in HRQoL were in the pain domain at all measured
time points, however consistent with other domains this improved over
time (pre-diagnosis 69.0%, three-months 59.4%, 12-months 51.2%
reporting problems).
The strength of this study lies in its uniqueness in assessing not only
those with significant and advanced liver disease, but also those at high-
risk and yet to develop fibrosis. To our knowledge, it is the first study to
assess the impact of a ‘screening’ pathway leading to the diagnosis of
chronic liver disease. The sample is shown to be representative of the
target population (those attending the Nottingham Liver Pathway), with
a good response rate (60%), reducing the risk of selection bias at follow-
up. What remains unknown is any understanding of the GP decision
making process prior to and patient acceptance of referral. As such, this
data only reflect those referred to the pathway and not all those poten-
tially eligible to be referred.
The majority of attempts to contact participants for three and 12
month follow-up were made during the working day. Multiple attempts
to contact were made (minimum three) and the time of day was varied.
However, this could have resulted in a bias towards inclusion at follow-
up of those unable to work or participate in activities leading to an under-
estimate of HRQoL. However, given the similarity in pre-diagnostic
characteristics of those with and without follow-up, and the confirma-
tory findings in the sensitivity analysis, we feel this bias is minimised. As
with any HRQoL study, unless a disease specific questionnaire is used
there is no way of knowing how much liver disease is contributing to the
overall score. However, the similarity of scores between different referral
groups suggests that despite different background co-morbidities the
score holds. It may be of value to investigate HRQoL in this population
using a disease specific score, however questionnaires such as the
Chronic Liver Disease Questionnaire [18] are highly focussed on
advanced symptoms of liver disease and may not be valid in populations
such as ours. Our results through the use of EQ-5D (and its inherent
ability to be compared across disease areas) are of value more widely due
Fig. 3. EQ-5D domains over time by fibrosis category.
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national level.
Identifying that patients with advanced liver disease have signifi-
cantly lower HRQoL than those with less severe disease is in keeping with
the work of others [4,19,20]. However, all prior studies only examined
the advanced end of the disease spectrum – in patients with established
chronic liver disease, typically around the time of transplantation. Our
work demonstrates that this gradient is apparent much earlier in the
disease history – including prior to diagnosis. Younessi’s 2019 study [19]
reported on patients with non-alcoholic steatosis from within phase 3
trials and found similar EQ-5D utility index measures to ourselves for F3
and F4 fibrosis (0.84 and 0.82 respectively). It is perhaps surprising that
we found no relationship between referral reason and HRQoL given that
prior studies [4,20] have repeatedly shown liver disease aetiology to be a
predictor of HRQoL, with NALFD having poorer scores than ARLD. It may
be that in this study the patients with ARLD disproportionately reflect
those with more severe fibrosis. However, one could speculate that
referral would be biased towards those with ARLD most likely to engage
in the pathway and have a higher HRQoL, thus leading the results to be
closer to the prior findings.
It is unclear what is driving the predominant loss of HRQoL in the
pain domain. Prior studies have also noted pain as a major contributor to
ill-health and health service utilisation amongst people with liver disease
[21], however this usually relates to advanced cirrhosis with ascites
related pain [22] and difficulties with analgesia prescription [23]. It
could be hypothesised that the improvements in mobility and activities of
daily living domains could be proxies of lifestyle changes triggered by the
liver diagnosis pathway. However, this is speculative and requires further
investigation.65. Conclusion/recommendations
There was no evidence from our study that patients participating in a
risk factor driven liver disease diagnosis pathway experienced any
detriment to HRQoL from the process. Given the growing burden of
undiagnosed CLD our findings provide support for role out of early
diagnostic pathways.
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